On December 16, 2024, Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough, announced the pricing of its underwritten offering of 12,500,000 shares of its common stock at a price to investors of $4.00 per share. The aggregate gross proceeds to Trevi were $50 million before deducting underwriting discounts and commissions and other offering expenses payable by Trevi.

The WilmerHale team representing Trevi consisted of Stuart Falber, Jeffries Oliver-Li, Erin Bruynell Gallagher, Matt Kosior and Amy O’Connell, with assistance from Meghan Walsh, Heidi Treiber, Tim Silva, Annaka Merrick and Lorri Strizich.